FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAmarin Corporation plc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AMRN
Amarin Corporation plc Stock AnalysisComprehensive stock analysis for Amarin Corporation plc (AMRN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAMRN
AMRN
Amarin Corporation plc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AMRN
  1. Home
  2. Stocks
  3. Amarin Corporation plc

Amarin Corporation plc

🇺🇸AMRN•NASDAQ

Amarin Corporation plc

🇺🇸AMRN•NASDAQ
Market cap
$232.89M

Your view on AMRN

Mkt Cap
$232.89M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Amarin Corporation plc

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Aaron D. Berg
Headquarters
Grand Canal Docklands, Dublin, IE
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Aaron D. Berg
Headquarters
Grand Canal Docklands, Dublin, IE
Description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates.

Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers.

It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.

Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Amarin Corporation plc. Starting points for Amarin Corporation plc: EPS -$0.92, beta 0.79 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Amarin Corporation plc. Trailing twelve-month EPS for Amarin Corporation plc stands at -$0.92. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$2.17average of analysts' targets
Current price—

Hold

Targets, low to high

$2.17

Low $1.50

Middle $2.00

High $3.00

Analyst ratings

18 ratings
  • Strong Buy0
  • Buy3
  • Hold13
  • Sell2
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.08−$0.01−$1.13−$0.63
Lowest estimate−$0.09−$0.01−$1.15−$0.64
Highest estimate−$0.08−$0.01−$1.11−$0.62
Number of analysts1111
A year ago$0.011−$0.091−$36.001—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$49.90M$43.23M$183.35M$189.05M
Lowest estimate$47.61M$42.71M$180.35M$175.87M
Highest estimate$52.19M$43.74M$186.35M$202.23M
Number of analysts1111
A year ago$49.15M$45.13M$213.65M—
Growth vs a year ago+1.5%−4.2%−14.2%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Amarin Corporation plc. Amarin Corporation plc has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AMRN20 companies · 2 funds
Compare AMRN with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACIUAC Immune S.A.HealthcareBiotechnology$213.7M
ALTAltimmune, Inc.HealthcareBiotechnology$270.5M
ANROAlto Neuroscience, Inc.HealthcareBiotechnology$1.0B
CLLSCellectis S.A.HealthcareBiotechnology$103.8M
DBVTDBV Technologies S.A.HealthcareBiotechnology$231.6M
ENGNenGene Holdings Inc.HealthcareBiotechnology$124.0M
KRROKorro Bio, Inc.HealthcareBiotechnology$170.7M
LRMRLarimar Therapeutics, Inc.HealthcareBiotechnology$337.4M
More Drug Manufacturers - General companies
TickerTypeCompanySectorExchangeMkt cap
NONOFNovo Nordisk A/SHealthcareOTC$168.6B
NVONovo Nordisk A/SHealthcareNYSE$173.8B
NVSNovartis AGHealthcareNYSE$293.1B
NVSEFNovartis AGHealthcareOTC$316.8B
OGNOrganon & Co.HealthcareNYSE$3.7B
OPHLFOno Pharmaceutical Co., Ltd.HealthcareOTC$7.8B
OPHLYOno Pharmaceutical Co., Ltd.HealthcareOTC$7.9B
ORINFOrion OyjHealthcareOTC$11.1B
ORINYOrion OyjHealthcareOTC$22.8B
OTSKFOtsuka Holdings Co., Ltd.HealthcareOTC$35.4B
OTSKYOtsuka Holdings Co., Ltd.HealthcareOTC$36.6B
PFEPfizer Inc.HealthcareNYSE$159.9B
ETFs holding Amarin Corporation plc
TickerFundFund assets% of the fund
SPDWState Street SPDR Portfolio Developed World ex-US ETF$41.0B in assets0.00%
GWXState Street SPDR S&P International Small Cap ETF$882M in assets0.01%

Largest holders first, then the funds most concentrated in AMRN.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Amarin Corporation plc, and how their positions are changing. At a $232.9M market value, institutional positions materially move Amarin Corporation plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Amarin Corporation plc executives and directors. Shares of Amarin Corporation plc have traded between $7.00 and $20.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Amarin Corporation plc. Coverage tracks Amarin Corporation plc within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Amarin Corporation plc.

AMRN AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1